The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

Mon, 08th Feb 2021 10:46

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Omega Diagnostics, up 40% at 96.98 pence, 12-month range 5.93p-126.95p. It will continue to modify its Alva-based facility to "upscale significantly" its lateral flow test production capacity as it noted a Financial Times article. The FT said the UK government has chosen three British companies to make rapid Covid-19 tests. The newspaper said Omega, SureScreen and Global Access Diagnostics have been selected by the Department of Health to produce up to 2 million lateral flow devices per day for the UK, according to two people briefed on the decision.

----------

Avacta Group, up 6.8% at 136.20 pence, 12-month range 13.00p-215.25p. Says it has entered into a commercial partnership with Mologic to accelerate to market Avacta's AffiDX SARS-CoV-2 lateral flow rapid antigen test. The pre-clinical stage biotechnology company said the partnership will provide the AffiDX antigen test a faster route to market by giving it a CE marking for professional use under rapid diagnostics firm Mologic's ISO13485 quality system.

----------

Tower Resources, up 11% at 0.56 pence, 12-month range 0.189p-0.650p. Notes its South African unit Rift Petroleum has received an updated resource at the offshore Algoa-Gamtoos license from partner New Age Energy Algoa. After reprocessing seismic data at the asset, overall portfolio volumes are 54% higher at Algoa-Gamtoos, Tower explained.

----------

AIM - LOSERS

----------

Bahamas Petroleum, down 67% at 0.68p, 12-month range 0.500p-5.722p. Bahamas said that while the Perseverance #1 well encountered hydrocarbons, commercial volumes of oil were not proven. The company said the Perseverance #1 well in the Bahamas encountered hydrocarbons, as well as successfully validating the structural model and the petroleum system. However, volumes of oil encountered "are not commercial".

----------

Tissue Regenix, down 12% at 0.65p, 12-month range 0.275p-1.280p. The company expects a revenue fall in 2020, citing the negative impact of the Covid-19 pandemic. The medical devices company expects revenue of GBP12.8 million, down 1.5% from 2019's GBP13.0 million. Its financial performance was "impacted by the ongoing coronavirus pandemic".

----------

Inland Homes, down 10% at 57.75p, 12-month range 32.00p-89.85p. The company reported a fall in full-year profit as activity was disrupted by the coronavirus pandemic. Its EPRA net asset value per share at the end of September 2020 was 103.97 pence per share, down 8.5% on a year ago due to a placing of 20.8 million new shares during the year. In a separate release, Inland Homes said Chair Terry Roydon will be standing down from the board at the conclusion of the company's annual general meeting in March. Senior Independent Director Simon Bennett will be promoted to chair,

----------

boohoo Group, down 4.5% at 348.40p, 12-month range 133.10p-433.50p. The AIM-listed online-only fashion retailer will be buying the e-commerce and digital assets and associated intellectual property rights, including customer data, related business information and inventory, of the Burton, Dorothy Perkins and Wallis brands. The GBP25.2 million deal to acquire the former Arcadia Group brands does not include any stores. boohoo said Monday's acquisition is a "significant opportunity to grow" its market share.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Sep 2022 12:01

Avacta cancer drug candidate AVA6000 advances to fourth dose cohort

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its fourth dose cohort.

Read more
21 Jul 2022 15:29

Avacta joint venture completes fresh funding round

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Thursday that AffyXell, its joint venture with Daewoong Pharmaceuticals, has completed a funding round to advance its lead mesenchymal stem cell (MSC) programme towards the clinic, and to develop its wider preclinical pipeline of cell therapies.

Read more
21 Jul 2022 12:17

Avacta joint venture completes funding for lead cell therapy programme

(Alliance News) - Avacta Group PLC on Thursday said that its joint venture AffyXell with Daewoong Pharmaceuticals Co Ltd has successfully completed a funding round.

Read more
30 Jun 2022 11:22

Avacta's partner LG Chem renews licence to develop Affimer platform

(Alliance News) - Avacta Group PLC said on Thursday that LG Chem Life Sciences has exercised its renewal option as part of an ongoing collaboration with the company, triggering a fee payment of USD2 million to Avacta.

Read more
29 Jun 2022 11:38

AIM WINNERS & LOSERS: Deltic rises on Shell deal; Windar down on delay

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
29 Jun 2022 10:21

Avacta shares up as cancer drug AVA6000 advances to third dose cohort

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its third dose cohort after "a positive review of the safety data" from the second cohort.

Read more
16 Jun 2022 16:03

UK shareholder meetings calendar - next 7 days

Friday 17 June 
Blackstone Loan Financing LtdAGM
boohoo Group PLCAGM
Directa Plus PLCAGM
Tesco PLCAGM
EnQuest PLCAGM
Octopus Renewables Infrastructure Trust PLCAGM
Monday 20 June 
Armadale Capital PLCAGM
Bank of Georgia Group PLCAGM
Globalworth Real Estate Investments LtdAGM
MetalNRG PLCAGM
Midatech Pharma PLCAGM
Silver Bullet Data Services Group PLCGM re fundraise
Venture Life Group PLCAGM
Tuesday 21 June 
1Spatial PLCAGM
Altus Strategies PLCAGM
Coca-Cola HBC AGAGM
FireAngel Safety Technology Group PLCAGM
HC Slingsby PLCAGM
HSS Hire Group PLCAGM
Mission Group PLCAGM
Novacyt SAAGM
Pendragon PLCAGM
RTW Venture Fund LtdAGM
Velocys PLCAGM
Wednesday 22 June 
ASA International Group PLCAGM
Atalaya Mining PLCAGM
Bonhill Group PLCAGM
Chapel Down Group PLCAGM
Churchill China PLCAGM
Downing Renewables & Infrastructure Trust PLCGM re share issue
Ecofin US Renewables Infrastructure Trust PLCAGM
EJF Investments LtdAGM
Frenkel Topping Group PLCAGM
Good Energy Group PLCAGM
Honeycomb Investment Trust PLCAGM
ICG-Longbow Senior Secured UK Property Debt Investments LtdAGM
Intelligent Ultrasound Group PLCAGM
Iofina PLCAGM
John Wood Group PLCAGM
Kingfisher PLCAGM
LXi REIT PLCGM
Menhaden PLCAGM
North Atlantic Smaller Cos Investment Trust PLCAGM
Pennant International Group PLCAGM
Plant Health Care PLCAGM
Skillcast Group PLCAGM
Team PLCAGM
Tribal Group PLCGM re final dividend
Trident Royalties PLCAGM
Vertu Motors PLCAGM
Wentworth Resources PLCAGM
Thursday 23 June 
Avacta Group PLCAGM
Anglo Asian Mining PLCAGM
Card Factory PLCAGM
Cordiant Digital Infrastructure LtdAGM
Downing Renewables & Infrastructure Trust PLCGM re initial placing & open offer
Eight Capital Partners PLCGM re aligning 2022 bonds with 2026 bonds
GENinCode PLCAGM
Ideagen PLCGM re takeover by Hg Pooled Management Ltd
Longboat Energy PLCAGM
Oxford Nanopore Technologies PLCAGM
Puma VCT 13 PLCGM re cancellation of listing & liquidation
RBG Holdings PLCAGM
Tandem Group PLCAGM
Zinnwald Lithium PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
16 May 2022 14:04

IN BRIEF: Avacta joint venture expands partnership with GenScript

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Says its joint venture AffyXell with Seoul, South Korea-based drug maker Daewoong Pharmaceutical Co Ltd expanded its partnership with GenScript ProBio. Says the partnership covers the process development and production of viral vectors required for the production of AffyXell's future cell therapy products. Adds that GenScript has now committed to take an equity position in AffyXell at a future funding round. The two companies will also collaborate in the area of business development, including potential out-licensing.

Read more
13 Apr 2022 17:33

Avacta increases shareholding in drug developer AffyXell to 22%

(Alliance News) - Avacta Group PLC said on Wednesday it increased its shareholding in its South Korean joint venture, AffyXell Therapeutics.

Read more
13 Apr 2022 13:57

Avacta triggers milestone in Daewoong joint venture

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Wednesday that a milestone equity payment has been triggered, resulting in an increase in its shareholding in AffyXell Therapeutics.

Read more
8 Apr 2022 16:17

Avacta joint venture enters new immune model collaboration

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Friday that AffyXell Therapeutics - its joint venture with Daewoong Pharmaceutical - has entered into a collaboration agreement with Chinese biological drugs developer Biocytogen and the Korea Non-Clinical Technology Solution Center (KNTSC).

Read more
8 Apr 2022 11:28

AIM WINNERS & LOSERS: Sensyne Health drops amid AIM delisting warning

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
8 Apr 2022 10:37

Avacta joint venture to collaborate with Chinese biological company

(Alliance News) - Avacta Group PLC said on Friday its joint venture has found a Chinese collaborator to develop new biologic drugs.

Read more
6 Apr 2022 10:23

IN BRIEF: Avacta widens annual loss on research, manufacturing costs

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Posts widened loss in 2021. Pretax loss expands to GBP29.2 million from GBP18.9 million in 2020. However, revenue rises to GBP2.9 million from GBP2.1 million. Like the year before, there will be no dividends.

Read more
16 Mar 2022 13:02

Avacta offloads animal health unit in £2.3m deal

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that Vimian Group has acquired its veterinary division, Avacta Animal Health, for consideration of up to £2.3m.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.